Poxel's TWYMEEG Sales Surge 36% in Japan, Royalties to Fuel Debt Repayment
Event summary
- TWYMEEG® net sales in Japan rose 36% YoY to €12.8M in Q1 2026, with Sumitomo Pharma targeting >€83M annual sales.
- Poxel received €1.28M in Q1 royalties (10% of net sales), with 12% rate expected for FY2026.
- Sumitomo Pharma expanded TWYMEEG® labeling for renal-impaired diabetes patients after post-marketing study success.
- Poxel divested PXL770 to Scynexis for up to $196M, including $8M upfront and $8M near-term milestones.
The big picture
Poxel's strong Q1 performance reflects the commercial viability of its mitochondrial dysfunction platform, particularly in Japan's type 2 diabetes market. The Scynexis divestment signals strategic focus on core metabolic programs while addressing debt obligations. With patent protections extending to 2039, Poxel aims to leverage TWYMEEG's expanded labeling to drive mid-teens revenue growth.
What we're watching
- Royalty Monetization
- Whether Poxel can sustain 10%+ annual TWYMEEG growth to maximize OrbiMed bond repayment.
- Regulatory Expansion
- The pace at which Poxel secures imeglimin approvals beyond Japan, particularly in China.
- Pipeline Prioritization
- How Poxel allocates resources between MASH candidate PXL065 and other rare disease programs.
Related topics